

# Bruno Ledergerber

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5689071/bruno-ledergerber-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

216  
papers

18,311  
citations

63  
h-index

132  
g-index

225  
ext. papers

20,126  
ext. citations

7.5  
avg, IF

5.62  
L-index

#	Paper	IF	Citations
216	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 2145-2153	7	3
215	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2194-e2202	11.6	13
214	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2070-e2076	11.6	4
213	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 758-767	8	22
212	Impact of Delaying Antiretroviral Treatment during Primary HIV Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	1
211	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1597-1604	11.6	0
210	Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endo-graft infections. <i>JAC-Antimicrobial Resistance</i> , <b>2021</b> , 3, dlab041	2.9	
209	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , <b>2021</b> , 11, 4586	4.9	2
208	PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , <b>2021</b> , 11, 5065	4.9	2
207	Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endograft infections. <i>Scientific Reports</i> , <b>2021</b> , 11, 13747	4.9	1
206	PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , <b>2021</b> , 83, 102356	2.1	4
205	Editor's Choice - Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endograft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2021</b> , 62, 251-257	2.3	3
204	Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV. <i>Aids</i> , <b>2021</b> , 35, 2469-2480	3.5	1
203	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 884-889	11.6	7
202	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 884-887	11.6	4
201	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 637-645	7	10
200	Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2020</b> , 59, 972-981	2.3	13

199	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa438	1	3
198	Inadequate Perioperative Prophylaxis and Postsurgical Complications After Graft Implantation Are Important Risk Factors for Subsequent Vascular Graft Infections: Prospective Results From the Vascular Graft Infection Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 621-630	11.6	11
197	Comparing diagnostic accuracy of F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1359-1368	8.8	18
196	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 135-138	5.1	5
195	Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 708-716	11.6	21
194	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , <b>2018</b> , 39, 2147-2154	9.5	35
193	Estimating the treatment effect on the treated under time-dependent confounding in an application to the Swiss HIV Cohort Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , <b>2018</b> , 67, 103-125	1.5	2
192	Perioperative Antibiotic Prophylaxis Has No Effect on Time to Positivity and Proportion of Positive Samples: a Cohort Study of 64 Cutibacterium acnes Bone and Joint Infections. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	8
191	The role of FDG PET/CT in therapy control of aortic graft infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1987-1997	8.8	20
190	Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , <b>2017</b> , 73, 294-304	1.8	7
189	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , <b>2017</b> , 7, e014679	3	6
188	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx177	1	5
187	Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 490-497	11.6	28
186	Optimal Length of Cultivation Time for Isolation of Propionibacterium acnes in Suspected Bone and Joint Infections Is More than 7 Days. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 3043-3049	9.7	66
185	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5094	1.8	19
184	Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. <i>Infection</i> , <b>2016</b> , 44, 521-9	5.8	5
183	Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw101	1	3
182	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw009	1	16

181	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw089	1	10
180	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 573-80	13.4	31
179	Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <i>AIDS Research and Therapy</i> , <b>2015</b> , 12, 4	3	13
178	Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. <i>Aids</i> , <b>2015</b> , 29, 231-8	3.5	26
177	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3323-31	5.1	5
176	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv108	1	31
175	The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. <i>Aids</i> , <b>2015</b> , 29, 2509-15	3.5	60
174	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , <b>2015</b> , 18, 20317	5.4	41
173	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133028	3.7	13
172	Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). <i>PLoS ONE</i> , <b>2015</b> , 10, e0140943	3.7	28
171	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 28-38	7	49
170	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133879	3.7	5
169	Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142923	3.7	21
168	Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. <i>Journal of Virology</i> , <b>2014</b> , 88, 763-7	6.6	25
167	Accounting for baseline differences and measurement error in the analysis of change over time. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 2-16	2.3	3
166	Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 1555-61	7	13
165	Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2363-8	5.9	26
164	Prevalence and predictors for homo- and heterosubtypic antibodies against influenza A virus. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1386-93	11.6	8

163	Role of microRNA modulation in the interferon- $\lambda$ 1-tribavirin suppression of HIV-1 in vivo. <i>PLoS ONE</i> , <b>2014</b> , 9, e109220	3.7	7
162	Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19667	5.4	4
161	Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19768	5.4	9
160	Antibiotic susceptibility of <i>Clostridium difficile</i> is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 607	4	20
159	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, ofu040	1	41
158	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , <b>2014</b> , 2, E318-29	2.5	13
157	Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 285-94	11.6	67
156	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 887-96	7.8	27
155	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , <b>2013</b> , 27, 907-918	3.5	12
154	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 759-67	7	6
153	Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 870-9	11.6	38
152	Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 62, 28-35	3.1	74
151	Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 64, e14-5	3.1	1
150	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. <i>PLoS ONE</i> , <b>2013</b> , 8, e74024	3.7	11
149	Causality, mediation and time: a dynamic viewpoint. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>2012</b> , 175, 831-861	2.1	51
148	Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis. <i>AIDS and Behavior</i> , <b>2012</b> , 16, 245-55	4.3	15
147	Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2390-8	27.4	74
146	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , <b>2012</b> , 12, 119-27	25.5	33

145	Predictive cross-validation for the choice of linear mixed-effects models with application to data from the Swiss HIV Cohort Study. <i>Biometrics</i> , <b>2012</b> , 68, 53-61	1.8	8
144	Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. <i>PLoS ONE</i> , <b>2012</b> , 7, e37983	3.7	11
143	Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. <i>PLoS ONE</i> , <b>2012</b> , 7, e44454	3.7	383
142	Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. <i>PLoS ONE</i> , <b>2012</b> , 7, e50307	3.7	14
141	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , <b>2012</b> , 41, 1807-20	7.8	31
140	Role of retroviral restriction factors in the interferon- $\gamma$ -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 3035-40	11.5	107
139	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 1313-21		26
138	Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 131-40	11.6	30
137	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. <i>Aids</i> , <b>2012</b> , 26, 193-205	3.5	67
136	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. <i>Aids</i> , <b>2012</b> , 26, 315-23	3.5	25
135	Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1541-50	1.6	7
134	Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 105-12	3.1	6
133	Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 294-9	3.1	12
132	Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 56, 36-43	3.1	129
131	Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 57, 24-31	3.1	15
130	A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. <i>HIV Clinical Trials</i> , <b>2011</b> , 12, 109-17		26
129	Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , <b>2011</b> , 30, 2947-58	2.3	11
128	No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipotrophy. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 620-4	7	10

127	Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 791-7	7	8
126	The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1095-103	7	60
125	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , <b>2011</b> , 60, 1506-19	19.2	52
124	Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1130-9	11.6	433
123	Noncirrhotic portal hypertension and didanosine: a re-analysis. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 154-51.6	11.6	11
122	Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1143-52	11.6	47
121	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 246-57	7	80
120	Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 532-9	11.6	99
119	Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. <i>PLoS ONE</i> , <b>2011</b> , 6, e27919	3.7	46
118	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 217-30	1.9	91
117	Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. <i>PLoS ONE</i> , <b>2010</b> , 5, e14011	3.7	63
116	Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 1314-22	11.6	73
115	Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 1090-8	11.6	21
114	Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1054-62	7	25
113	Reply to Chang and Garcia-Pagan. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 128-129	11.6	2
112	Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1488-97	7	145
111	HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 620-8	11.6	24
110	Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 502-11	11.6	77

109	Cohort profile: the Swiss HIV Cohort study. <i>International Journal of Epidemiology</i> , <b>2010</b> , 39, 1179-89	7.8	282
108	Reply to Kuniholm et al. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1546-1547	11.6	
107	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , <b>2010</b> , 24, 1667-78	3.5	307
106	Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 53, 464-71	3.1	16
105	Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 262-70	3.1	203
104	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , <b>2010</b> , 376, 340-5 <sup>40</sup>		77
103	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 410-9		35
102	High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. <i>Aids</i> , <b>2010</b> , 24, 1127-34	3.5	146
101	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 413-23	1.6	134
100	Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 563-70	1.6	9
99	HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 1077-86	1.6	33
98	Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 57-65		111
97	A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , <b>2010</b> , 29, 2757-68	2.3	45
96	Risk factors for urinary tract infections due to ciprofloxacin-resistant <i>Escherichia coli</i> in a tertiary care urology department in Switzerland. <i>Swiss Medical Weekly</i> , <b>2010</b> , 140, w13059	3.1	14
95	Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 626-35	11.6	104
94	Common genetic variation and the control of HIV-1 in humans. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000791	6	310
93	Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 979-87	11.6	41
92	Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. <i>Circulation: Cardiovascular Genetics</i> , <b>2009</b> , 2, 621-8		32



91	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , <b>2009</b> , 373, 1352-63	40	580
90	African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. <i>Aids</i> , <b>2009</b> , 23, 1269-76	3.5	27
89	Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 50, 457-63	3.1	47
88	Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. <i>PLoS ONE</i> , <b>2009</b> , 4, e8275	3.7	16
87	HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. <i>Aids</i> , <b>2008</b> , 22, 469-79	3.5	55
86	Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1685-94	7	83
85	Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1299-309	11.6	29
84	Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1451-61	5.1	36
83	Correlation between case mix index and antibiotic use in hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 837-42	5.1	57
82	Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1337-44	7.44	127
81	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , <b>2008</b> , 22, 767-75	3.5	35
80	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , <b>2008</b> , 22, 2135-43	3.4	121
79	Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. <i>PLoS Medicine</i> , <b>2008</b> , 5, e203	11.6	1179
78	Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. <i>PLoS Medicine</i> , <b>2008</b> , 5, e148	11.6	99
77	Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 111-9	11.6	201
76	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , <b>2007</b> , 21, 2223-9	3.5	100
75	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , <b>2007</b> , 36, 1309-18	7.8	17
74	Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 1782-90		95

73	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , <b>2007</b> , 21, 1867-75	3.5	34
72	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , <b>2007</b> , 21, 1185-97	3.5	218
71	A whole-genome association study of major determinants for host control of HIV-1. <i>Science</i> , <b>2007</b> , 317, 944-7	33.3	999
70	Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. <i>PLoS ONE</i> , <b>2007</b> , 2, e173	3.7	24
69	Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 633-41	7	63
68	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41		869
67	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , <b>2006</b> , 20, 1141-50	3.5	34
66	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , <b>2006</b> , 20, 889-94	3.5	45
65	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 305-14	1.6	4
64	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 305-314	1.6	5
63	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 567-574	1.6	25
62	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 131-142	1.6	22
61	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , <b>2005</b> , 19, 593-601	3.5	390
60	Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. <i>Lancet, The</i> , <b>2005</b> , 366, 378-84	4.0	458
59	Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 992-1002	7	319
58	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , <b>2005</b> , 19, 1987-94	3.5	25
57	The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 416-23		103
56	Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 1419-26	7	92

55	Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 721-8	11.6	29
54	Characteristics, determinants, and clinical relevance of CD4 T cell recovery to . <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 361-72	11.6	257
53	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 791-802	1.6	40
52	Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 1178-85	11.6	153
51	Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. <i>AIDS Research and Human Retroviruses</i> , <b>2004</b> , 20, 909-15	1.6	24
50	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , <b>2004</b> , 364, 51-62	4.0	267
49	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , <b>2004</b> , 18, 1795-804	3.5	22
48	Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. <i>Aids</i> , <b>2004</b> , 18, 2333-7	3.5	27
47	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , <b>2004</b> , 18, 2213-5	3.5	12
46	HIV cohort collaborations: proposal for harmonization of data exchange. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 631-3.6		16
45	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 85-95	1.6	43
44	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 263-274	1.6	5
43	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 787-800	1.6	2
42	HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 33, 292-9	3.1	35
41	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 1741-51	3.5	83
40	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. <i>Aids</i> , <b>2003</b> , 17, 2237-44	3.5	61
39	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet, The</i> , <b>2003</b> , 362, 877-8	4.0	91
38	CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 2187-95		284

37	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 443-54	1.6	8
36	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 127-136	1.6	18
35	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 443-454	1.6	18
34	Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 189-97	7	48
33	Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. <i>Aids</i> , <b>2002</b> , 16, 381-5	3.5	21
32	A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 178-87	7	108
31	A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 1251-60	7	121
30	Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. <i>Annals of Internal Medicine</i> , <b>2002</b> , 137, 239-50	8	98
29	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. <i>Aids</i> , <b>2002</b> , 16, 1371-81	3.5	80
28	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. <i>Aids</i> , <b>2002</b> , 16, 747-55	3.5	36
27	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , <b>2002</b> , 360, 119-29	40	1246
26	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , <b>2002</b> , 16, 1967-9	3.5	88
25	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 26, 397-404	3.1	12
24	Discontinuation of secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 168-74	59.2	127
23	HIV-1 progression in hepatitis-C-infected drug users. <i>Lancet, The</i> , <b>2001</b> , 357, 1363	40	2
22	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , <b>2001</b> , 358, 1322-7	40	280
21	Importance of mental health assessment in HIV-infected outpatients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 28, 240-9	3.1	36
20	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , <b>2001</b> , 15, 2385-95	3.5	49

19	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , <b>2001</b> , 15, 1793-800	3.5	33
18	Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. <i>Aids</i> , <b>2000</b> , 14, 2145-51	3.5	22
17	Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , <b>2000</b> , 14, 1409-12	3.5	21
16	Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1280-8	7	64
15	Intestinal infection due to enteroaggregative Escherichia coli among human immunodeficiency virus-infected persons. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 1540-4	7	33
14	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. <i>Aids</i> , <b>1999</b> , 13, 943-50	3.5	271
13	Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1999</b> , 22, 56-64		22
12	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. <i>JAMA - Journal of the American Medical Association</i> , <b>1999</b> , 282, 2220-6	27.4	341
11	Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 1631-8	1.6	72
10	Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 23-4		182
9	Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study. <i>Lancet, The</i> , <b>1999</b> , 353, 589; author reply 590-1	40	49
8	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. <i>Lancet, The</i> , <b>1999</b> , 353, 863-8	40	812
7	Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. <i>Lancet, The</i> , <b>1999</b> , 353, 1293-8	40	174
6	Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. <i>Aids</i> , <b>1999</b> , 13, 2281-8	3.5	19
5	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. <i>Aids</i> , <b>1999</b> , 13, 1587-9	3.5	19
4	Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study. <i>Aids</i> , <b>1998</b> , 12, 2253-60	3.5	31
3	Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 16, 153-60		45
2	The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. <i>International Journal of Public Health</i> , <b>1994</b> , 39, 387-94		102

- 1 Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. *Aids*, **1994**, 8, 1307-13 3.5 38